BHCM
MRSN

Boulder Hill Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Boulder Hill Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-920
Closed -$135K – 188
2022
Q4 		$135K Buy
+920
New +$155K 0.11% 115

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Boulder Hill Capital Management's MRSN Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 920 shares — an estimated $135K sold.

Boulder Hill Capital Management first reported a position in MRSN in Q4 2022 and held it in 1 quarter. The position peaked at $135K in Q4 2022. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 920 Mersana Therapeutics shares in Q1 2023, an estimated $135K.
  • Boulder Hill Capital Management first reported a position in Mersana Therapeutics in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Mersana Therapeutics position peaked at $135K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.